Human leukocyte antigen class I and class II alleles are associated with susceptibility and resistance in borderline leprosy patients from Southeast Brazil

Table 2 HLA alleles with statistically significant differences in BB, BT, and BL patients and healthy controls

BB	HLA allele	Patients (N = 88)		Controls (N = 478)		p	pc	OR	IC
		N	%	n	%
	*B49**	0	0.00	29	6.07	0.014	0.448	0.09	0.005–1.42
	*B58**	10	11.36	24	5.03	0.028	0.896	2.42	1.11–5.27
	*C05**	5	5.68	67	14.02	0.035	0.49	0.37	0.14–0.94
	*C12**	19	21.59	64	13.39	0.050	0.70	1.78	1.00–3.15
BT		Patients (N = 70)		Controls (N = 478)
	*A33**	8	11.43	25	5.23	0.056	1.12	2.34	1.01–5.41
	*B40**	2	2.86	50	10.46	0.047	1.50	0.25	0.06–1.06
	*B49**	0	0.00	29	6.07	0.039	1.24	0.11	0.006–1.79
	*B53**	6	8.57	14	2.93	0.031	0.992	3.11	1.15–8.37
	*C05**	3	4.28	67	14.02	0.020	0.28	0.27	0.08–0.89
	*C16**	9	12.86	26	5.44	0.031	0.434	2.56	1.15–5.73
	*DRB103**	20	28.57	85	17.78	0.049	0.637	1.85	1.05–3.27
BL		Patients (N = 44)		Controls (N = 478)
	*B53**	4	9.09	14	2.93	0.056	1.792	3.31	1.04–10.54
	*DRB107**	5	11.36	128	26.77	0.028	0.364	0.35	0.13–0.91
	*DQB102**	8	18.18	189	39.53	0.005	0.025	0.34	0.15–0.75

N: number of individuals, n: number of alleles (2n), %: allele frequency, p: Fisher’s exact test (p ≤ 0.05), pc: corrected p value, OR: odds ratio, CI: confidence interval, boldface: significant association after Bonferroni´s correction.

ISSN: 1471-2334